Yale University

Davis Phinney Foundation and Michael J. Fox Foundation: NEW Exercise Guidelines for Parkinson's: Taking the Next Step, Putting Guidelines into Action with Urban Poling Inc.

Retrieved on: 
Monday, April 15, 2024
Amazon (company), Pain, Brain, Parkinson's disease, Risk, Heart, Davis Phinney Foundation, Gait, Exercise, Yale University, Disease, Fatigue, College, Movement, Multimedia, Community, Associate, Urban, PD, Walking

TORONTO, April 15, 2024 /PRNewswire/ -- The Davis Phinney Foundation and Michael J Fox Foundation have recently released exercise guidelines for people with Parkinson's through informative and inspiring webinars.

Key Points: 
  • TORONTO, April 15, 2024 /PRNewswire/ -- The Davis Phinney Foundation and Michael J Fox Foundation have recently released exercise guidelines for people with Parkinson's through informative and inspiring webinars.
  • The key is in finding the type of physical activity that most appeals to the individual to ensure continuity and progression over time.
  • Although movement is part of daily living, a greater commitment to exercise is essential, especially with today's sedentary lifestyles.
  • No matter the type, if the activity is enjoyable and easy to commit to, it can be a game changer.

Earth Day Month: MRA Highlights Research That Shows How Homeowners Can Lessen Environmental Impacts, One Rooftop At A Time

Retrieved on: 
Tuesday, April 9, 2024
Copper, Steel, Yale University, Ice, Transport, Climate, Heat, Snow, Disaster, Mars Climate Orbiter, Environment, Water pollution, MRA, Earth Day, Metal, Aluminium, Metal Construction Association, Mining, Recycling, Air pollution

PORTLAND, Ore., April 9, 2024 /PRNewswire-PRWeb/ -- The month of April and celebrating Earth Day are perfect reminders of how every improvement decision homeowners make has a major impact on the planet.

Key Points: 
  • PORTLAND, Ore., April 9, 2024 /PRNewswire-PRWeb/ -- The month of April and celebrating Earth Day are perfect reminders of how every improvement decision homeowners make has a major impact on the planet.
  • It is estimated that more than 13 million tons of asphalt shingles get dumped in landfills each year.
  • According to the Metal Construction Association*, recycling decreases the amount of energy required to produce metal products like metal roofing.
  • The minimum amount of recycled content metal roofs contain is 25 percent, and most have percentages that are substantially higher.

Gretel Releases World’s Largest Open Source Text-to-SQL Dataset to Accelerate AI Model Training

Retrieved on: 
Thursday, April 4, 2024
Blood pressure, Hugging Face, SQL, Spider, Yale University, MIT, Patient, SAN, Head, Ageing, Blog, AI, Student, LLM, Statistics, Clinical trial, Language, Data, Metadata, Population growth, Mobile phone

SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Gretel , the leader in synthetic data, today released the world’s largest open source Text-to-SQL dataset to unlock new possibilities for AI in the enterprise.

Key Points: 
  • SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Gretel , the leader in synthetic data, today released the world’s largest open source Text-to-SQL dataset to unlock new possibilities for AI in the enterprise.
  • "Access to quality training data is one of the biggest obstacles to building with generative AI.
  • Everything Gretel does is designed to address this issue head-on, and contributing to the open-source community is no exception," said Alex Watson, co-founder & Chief Product Officer at Gretel.
  • We’re excited for developers to take our dataset for a spin, and build upon it.”
    The largest AI companies in the world are struggling with access to high-quality training data.

Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure

Retrieved on: 
Wednesday, April 3, 2024
Cardiorenal syndrome, Congestion, DSR, Brussels Stock Exchange, Liver disease, Associate, RED, Patient, NYHA, Mortality, Cancer, Fluid, Heart failure, European Journal, Diuretic, Overload, Syndrome, Yale University, Pharmaceutical industry

The publication can be accessed here .

Key Points: 
  • The publication can be accessed here .
  • Dr. Jeffrey Testani, Associate professor at Yale University and senior author of the publication commented: “Cardiorenal syndrome is a major clinical challenge in heart failure with a clear unmet need for therapies to effectively and durably address congestion and cardio-renal dysfunction.
  • Currently the mainstay of therapy for sodium avidity and congestion are the loop diuretics, which actually worsen sodium avidity and cardiorenal syndrome.
  • Diuretic-resistant heart failure and cardiorneal syndrome are large and growing markets both in the US and rest of world, with the clear need for novel treatments that can improve clinical outcomes beyond loop diuretics.

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 2, 2024
Research, Failure, Plasma, KPMG, TDP43, Disease, PD, CSF, Yale University, Patient, Inflammation, Biomarker, CMC, Equity, TAR, Human, European, Drug development, ATM, Safety, Phase, Therapy, Vaccine, Treasury, Syneos Health, Axonal transport, Pharmaceutical industry

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.

Key Points: 
  • MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.
  • For the quarter ended December 31, 2023, Annovis reported a net loss of $22.2 million, compared to a net loss of $7.7 million for the same period in 2022.
  • For the full year ended 2023, Annovis reported a net loss of $56.2 million, compared to a net loss of $25.3 million in 2022.
  • Other income (expense) for the quarter ended December 31, 2023 was ($11.2) million, compared to $0.2 million for the same period in 2022.

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, March 28, 2024
Transcoding, Internal medicine, Temple University Hospital, CFO, Oncology, Patient, RNA, University, Cancer, University of Pittsburgh, Yale School of Medicine, Baylor College of Medicine, Infection, Therapy, Harvard University, Interim, Muscular dystrophy, Yale University, Pharmacia, Pharmaceutical industry

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.

Key Points: 
  • BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.
  • Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University.
  • While at Pharmacia, Dr. Vlock ran the Celebrex Oncology program involving two pivotal clinical trials and over 3,500 patients.
  • Dr. Vlock initially will serve on a part-time basis through TransCode’s arrangement with BioBridges LLC, a life sciences consulting company.

Tetricus Labs Partners with Silver Hill Hospital on Research to Advance Precision Psychiatry

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, Neurology, Mental Health, Research, Software, Artificial Intelligence, Hospitals, Science, Dow, Panic disorder, Psychiatry, Data science, Associate, Silver, Partnership, Patient, Tetricus, Bipolar disorder, Radiology, Neuroscience, Doctor of Philosophy, DSM-IV codes, Evercore, MD, Psychology, Silver Hill Hospital, Social anxiety disorder, Machine learning, Medical director, Yale University, Medicine, Nursing

Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.

Key Points: 
  • Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.
  • “We're patient-founded, patient-owned, and patient-run,” said Dow, CEO for Tetricus Labs.
  • Andrew J. Gerber, MD, PhD, President and Medical Director of Silver Hill Hospital, will join Tetricus Labs as a Medical Advisor to ensure Tetricus’ machine learning software is designed to fit within the busy workflow of hospital clinicians and staff, maximizing its accessibility for providers and potential impact on patient outcomes.
  • “This partnership represents our continued commitment to exploring innovative methods that can enhance our understanding of psychiatric disorders and improve patient outcomes."

Gennao Bio Debuts Preclinical Data for First-in-Class Antibody-Drug Conjugate from Gene Monoclonal Antibody Platform (GMAB ADC)

Retrieved on: 
Tuesday, April 9, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Human, Plasma, Survival, Yale University, Colorectal cancer, Neoplasm, DNA, Hepatotoxicity, Biology, AACR, ENT2, Cytoplasm, Yale school, Therapy, Poster, ADC, Vaccine

Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced new preclinical results on the application of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology as an antibody-drug conjugate (ADC) for the treatment of solid tumors.

Key Points: 
  • Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced new preclinical results on the application of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology as an antibody-drug conjugate (ADC) for the treatment of solid tumors.
  • The data were presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • In preclinical studies, our GMAB technology demonstrated selective delivery of payloads into tumors by targeting ENT2, a nucleoside transporter that is highly overexpressed in many tumors.
  • “These preclinical results reinforce the versatility of the GMAB platform and its ability to deliver therapeutic payloads beyond genetic medicine to targeted tissue,” Chris Duke, chief executive officer of Gennao.

Antitrust Lawyer Herb Allen Joins Honigman as Partner, Enhancing the Firm's Antitrust Capabilities

Retrieved on: 
Monday, April 8, 2024
Consulting, Professional Services, Legal, Vanderbilt University Law School, Honigman LLP, Justice minister, LLP, DOJ, Multimedia, Herb, Federal Trade Commission, Yale University, FTC

Honigman LLP announced today that Herb Allen has joined its Washington D.C. office as a partner in the firm’s antitrust group within the Litigation Department.

Key Points: 
  • Honigman LLP announced today that Herb Allen has joined its Washington D.C. office as a partner in the firm’s antitrust group within the Litigation Department.
  • Herb represents clients in antitrust litigation matters and defends M&A transactions under review by the Federal Trade Commission (FTC), Department of Justice (DOJ), and state antitrust enforcers.
  • "His deep expertise in antitrust matters will undoubtedly strengthen our offerings and elevate the services we provide to our clients."
  • Allen joins Honigman from Polsinelli PC, where he served as an Antitrust and Litigation Shareholder.

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne

Retrieved on: 
Tuesday, April 9, 2024
AbbVie, Antioxidant, MSRP, Nicotinamide, Physician, Patient, ABBV, Senior, Trial of the century, Acne, Skin, Aloe, Yale University, Salicylic acid, Cosmetics

The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin.

Key Points: 
  • The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin.
  • "The formulations of the new products continue the legacy of promoting skin health and addressing key patient concerns like acne."
  • In clinical studies, participants who used the SkinMedica® Acne Clarifying Treatment and Pore Purifying Gel Cleanser noticed clearer skin while reporting that the products did not dry their skin out.
  • "My patients often find themselves in a bind when choosing acne products that treat acne but don't compromise the skin barrier.